Bhagyashri Randhawan*
Javane Nalini
In June 2014, the USFDA advisory committee sanctioned the accelerated approval of olaparib. In December 2014, the USFDA approved olaparib for the treatment of advanced ovarian cancer. In August 2017, olaparib was approved for the maintenance treatment of ovarian cancer. In January 2018, it was approved for use in metastatic breast cancer with germline BRCA mutations. In December 2018, the USFDA approved olaparib for maintenance treatment in BRCA-mutated advanced ovarian cancer in the first-line setting. In December 2019, olaparib was approved for use as first-line maintenance treatment in metastatic pancreatic cancer with germline BRCA mutations. In May 2020, it was approved as maintenance treatment for homologous recombination deficiency-positive advanced ovarian cancer in the first-line setting in combination with bevacizumab and as a single agent for metastatic castration-resistant prostate cancer with mutations in the homologous recombination repair genes. [5]
OVARIAN CANCER
DNA mutations that allow cells to grow and proliferate quickly, eventually resulting in a tumour, are the first step in the development of ovarian cancer, a disease in which malignant cells grow in the ovaries. These cancerous cells can infiltrate adjacent tissues and travel to different bodily areas. The type of ovarian cancer and the available treatments are determined by the type of cell from which the cancer starts. A malignant growth in one or both ovaries is known as ovarian cancer. Although there are many different kinds of ovarian cancer, the three most prevalent ones are the common epithelial type, which develops from the cells outside the ovary in 90% of cases; the germ cell type, which develops from the cells that produce eggs in 4% of cases; and the uncommon stromal type, which develops from the ovary's supporting tissues.
10.5281/zenodo.16917622